Vaccinex Stock Analysis

Vaccinex Stock Analysis Notes

About 49.0% of the company outstanding shares are owned by institutional investors. The company recorded earning per share (EPS) of 7.42. Vaccinex had not issued any dividends in recent years. The entity had 1:14 split on the 20th of February 2024. Vaccinex, Inc., a clinical-stage biotechnology company, focuses on treating cancer and neurodegenerative disease through the inhibition of semaphorin 4D . Vaccinex, Inc. was incorporated in 2001 and is headquartered in Rochester, New York. Vaccinex operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs people. For more information please call Maurice Zauderer at 585 271 2700 or visit https://www.vaccinex.com.

Vaccinex Investment Alerts

Vaccinex Upcoming and Recent Events

Vaccinex Largest EPS Surprises

View All Earnings Estimates

Vaccinex Environmental, Social, and Governance (ESG) Scores

Vaccinex Thematic Classifications

Vaccinex Stock Institutional Investors

Note, although Vaccinex's institutional investors appear to be way more sophisticated than retail investors, it remains unclear if professional active investment managers can reliably enhance risk-adjusted returns by an amount that exceeds fees and expenses.

Vaccinex Market Capitalization

The company currently falls under 'Nano-Cap' category with a current market capitalization of 9.64 M.

Vaccinex Profitablity

Management Efficiency

Vaccinex has return on total asset (ROA) of (4.9564) % which means that it has lost $4.9564 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (7.5909) %, meaning that it created substantial loss on money invested by shareholders. Vaccinex's management efficiency ratios could be used to measure how well Vaccinex manages its routine affairs as well as how well it operates its assets and liabilities. At this time, Vaccinex's Return On Capital Employed is fairly stable compared to the past year. Return On Equity is likely to rise to 9.20 in 2024, whereas Return On Tangible Assets are likely to drop (5.86) in 2024. At this time, Vaccinex's Total Assets are fairly stable compared to the past year. Net Tangible Assets is likely to rise to about 8.9 M in 2024, whereas Non Currrent Assets Other are likely to drop (1.05) in 2024.

Technical Drivers

As of the 21st of November, Vaccinex has the Variance of 74.9, insignificant risk adjusted performance, and Coefficient Of Variation of (7,105). In relation to fundamental indicators, the technical analysis model makes it possible for you to check existing technical drivers of Vaccinex, as well as the relationship between them.

Vaccinex Price Movement Analysis

Vaccinex Insider Trading Activities

Vaccinex Outstanding Bonds

Vaccinex Predictive Daily Indicators

Vaccinex Corporate Filings

Vaccinex Forecast Models

Vaccinex's time-series forecasting models are one of many Vaccinex's stock analysis techniques aimed at predicting future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Vaccinex's historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.

Stock analysis is the technique used by a trader or investor to examine and evaluate how Vaccinex prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Vaccinex shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas. a specific sector, or an individual Stock such as Vaccinex. By using and applying Vaccinex Stock analysis, traders can create a robust methodology for identifying Vaccinex entry and exit points for their positions.

We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. Vaccinex analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. Vaccinex analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.

Vaccinex stock analysis indicators help investors evaluate how Vaccinex stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing and determine when trading Vaccinex shares will generate the highest return on investment. By understating and applying Vaccinex stock analysis, traders can identify Vaccinex position entry and exit signals to maximize returns.

When running Vaccinex's price analysis, check to measure Vaccinex's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Vaccinex is operating at the current time. Most of Vaccinex's value examination focuses on studying past and present price action to predict the probability of Vaccinex's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Vaccinex's price. Additionally, you may evaluate how the addition of Vaccinex to your portfolios can decrease your overall portfolio volatility.